Accueil / Tag Archives: Washington (page 20)

Tag Archives: Washington

Accelerator Corporation Announces $7M Series A Investment in ApoGen Biotechnologies to Develop a New Class of Drugs Targeting Resistance to Cancer Therapy

Monday, December 12th 2016 at 1:30pm UTC Third Accelerator Corporation-Backed Startup Launched in 2016 SEATTLE–(BUSINESS WIRE)– Accelerator Corporation, a leading life science investment and management firm, today announced an investment in ApoGen Biotechnologies, Inc., a company developing a new class of drugs that target the underlying mechanisms that cause genomic …

Plus »

Cancer Targeted Technology Commences Phase I Clinical Trial of CTT1057, a Diagnostic Imaging Agent for Prostate Cancer

Monday, December 12th 2016 at 2:30pm UTC SEATTLE–(BUSINESS WIRE)– Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on small molecules that target pivotal enzyme targets on cancer, announced that a Phase I clinical trial has commenced in men with high risk metastatic prostate cancer. In late August, the …

Plus »

Seattle Genetics Highlights Phase 1 Data for Novel Antibody-Drug Conjugate SGN-LIV1A in Patients with Metastatic Breast Cancer at San Antonio Breast Cancer Symposium

Saturday, December 10th 2016 at 1:30pm UTC -SGN-LIV1A Monotherapy Data Show 37 Percent Objective Response Rate in Heavily Pretreated Patients with Triple Negative Metastatic Breast Cancer- SAN ANTONIO–(BUSINESS WIRE)– Seattle Genetics, Inc. (NASDAQ: SGEN), a global biotechnology company, today presented data from an ongoing phase 1 clinical trial evaluating SGN-LIV1A …

Plus »

Visualant and BIOMEDX Sign Joint Development Agreement

Wednesday, December 7th 2016 at 2:00pm UTC Focus on ChromaID to Aid in Enhanced 3-D and Holographic Imaging for Certain Medical Procedures SEATTLE–(BUSINESS WIRE)– Visualant, Inc. (OTCQB: VSUL) – a photonics technology development company providing chromatic-based identification, authentication and diagnostic solutions, with its ChromaID™ technology, announced today that it has …

Plus »

Seattle Genetics Highlights Long-Term Follow-Up Data from ADCETRIS® (Brentuximab Vedotin) in T-Cell Lymphomas at ASH Annual Meeting

Monday, December 5th 2016 at 6:00pm UTC -Long-Term ADCETRIS Data Support Development Strategy to Establish ADCETRIS as Foundation of Care for CD30-Expressing Lymphomas- -ADCETRIS Pivotal Trial in Systemic Anaplastic Large Cell Lymphoma Shows Estimated Five-Year Survival Rate of 60 Percent with Majority of Patients Achieving Durable Remissions- -Phase 1 Trial …

Plus »

Listing of Kubota Pharmaceutical Holdings Co., Ltd. and Forecast for Fiscal Year End 2016

Monday, December 5th 2016 at 11:09pm UTC TOKYO–(BUSINESS WIRE)– Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo: 4596) (the “Company”) hereby gives notice that the merger agreement regarding its proposed redomicile transaction became effective on December 1, 2016 Japan Time. On December 6, 2016 Japan Time, the Company has been listed on …

Plus »

Juno Therapeutics Presents Data From TRANSCEND Study Showing 60% Complete Response in Patients with Relapsed or Refractory Aggressive CD19+ Non-Hodgkin Lymphoma

Monday, December 5th 2016 at 6:00pm UTC — 80% overall response and 60% complete response — No severe cytokine release syndrome to date and 14% rate of severe neurotoxicity — Side effect profile plus cell persistence suggest potential for combination therapy SEATTLE–(BUSINESS WIRE)– Juno Therapeutics, Inc. (NASDAQ:JUNO), a biopharmaceutical company …

Plus »

Omeros’ Proprietary Orphan GPCR Program Delivers New Target and Approach in Cancer Immunotherapy

Monday, December 5th 2016 at 12:00pm UTC — Small-Molecule Inhibitors Enhance Immune System and May Offer Advantages over Existing Cancer Therapies — SEATTLE–(BUSINESS WIRE)– Omeros Corporation (NASDAQ: OMER) today announced that its small-molecule inhibitors against GPR174, an orphan G protein-coupled receptor (GPCR) narrowly expressed in immune cells and linked to …

Plus »

Seattle Genetics Highlights Phase 1 Vadastuximab Talirine (SGN-CD33A; 33A) Data Presentations, Including Combination Therapy with HMAs, in Patients with Acute Myeloid Leukemia at ASH Annual Meeting

Monday, December 5th 2016 at 3:00pm UTC – Both Combination and Monotherapy Data Show 33A is Well-Tolerated with Rapid, High Remission Rates for AML Patients in Multiple Phase 1 Trials; Data Highlighted in Three Oral Presentations – – Addition of 33A to Hypomethylating Agents in Frontline Older AML Results in …

Plus »
>
Macbook Pro
* Intel Core i7 (3.8GHz, 6MB cache)
* Retina Display (2880 x 1880 px)
* NVIDIA GeForce GT 750M (Iris)
* 802.11ac Wi-Fi and Bluetooth 4.0
* Thunderbolt 2 (up to 20Gb/s)
* Faster All-Flash Storage (X1)
* Long Lasting Battery (9 hours)
BIENVENUE CHEZ BIOTECH FINANCES
Vous appréciez nos informations ?
Recevez nos alertes, nos dernières actualités, suivez-nous, enregistrez-vous gratuitement, rejoignez notre communauté. Merci à vous !
ARE YOU READY? GET IT NOW!
Increase more than 500% of Email Subscribers!
Your Information will never be shared with any third party.
DÉCOUVREZ LA SOLUTION STRATA !
PGlmcmFtZSB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBzcmM9Imh0dHBzOi8vd3d3LmJpb3RlY2gtZmluYW5jZXMuY29tL3dwLWNvbnRlbnQvdXBsb2Fkcy8yMDE1LzA3L1NhdHJhLTIubXA0IiBmcmFtZWJvcmRlcj0iMCIgYWxsb3dmdWxsc2NyZWVuPjwvaWZyYW1lPg==
Retrouvez nous sur http://stratahealth.com/fr/
Un ensemble de solutions performantes
pour assurer le continuum de vos données.
Biotech Finances
SUIVEZ-NOUS, ENREGISTREZ-VOUS !
PGlmcmFtZSB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBzcmM9Imh0dHA6Ly93d3cueW91dHViZS5jb20vZW1iZWQvajhsU2NITzJtTTAiIGZyYW1lYm9yZGVyPSIwIiBhbGxvd2Z1bGxzY3JlZW4+PC9pZnJhbWU+
All rights reserved © Company Name, 2014
Concours Genopole Young Biotech Award
* 100 000 € pour la meilleure Biotech
* Réservé aux biotechs hors santé
* 6 mois d'hébergement gratuit
* Un accompagnement personnalisé
* Etude de marché offerte
* Expertise du projet par EY
* Et nombre d'autres avantages...
S'inscrire au 15H BIOTECH EXPRESS
Chaque jour à 15H recevez gratuitement les news des biotechs, des medtechs,et des fonds spécialisés. Levées ; partenariats ; nominations ; fusacq ; closing ; milestone...
2019 (C) All rights reserved.

En cochant cette case, j’accepte la Politique de confidentialité de ce site et de recevoir des informations de notre part.

S'inscrire au 15H BIOTECH EXPRESS
Chaque jour à 15H recevez gratuitement les news des biotechs, des medtechs,et des fonds spécialisés. Levées ; partenariats ; nominations ; fusacq ; closing ; milestone...
2019 (C) All rights reserved.

En cochant cette case, j’accepte la Politique de confidentialité de ce site et de recevoir des informations de notre part.